Clearside Biomedical Receives a Buy from Cowen & Co.

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Clearside Biomedical (NASDAQ: CLSD). The company’s shares opened today at $12.53.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 18.2% and a 52.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $22.80.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.06 and a one-year low of $5.30. Currently, Clearside Biomedical has an average volume of 1.01M.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.